New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell CarcinomaBusiness Wire • 07/26/24
Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/25/24
Natera to Present at the 28th International Conference on Prenatal Diagnosis and TherapyBusiness Wire • 07/03/24
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal CancerBusiness Wire • 06/27/24
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant PatientsBusiness Wire • 06/17/24
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness Wire • 06/03/24
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024Business Wire • 05/30/24
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads ConferenceBusiness Wire • 05/23/24
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual MeetingBusiness Wire • 05/23/24
Why Natera Is 'A Stock To Focus On' Following Its Mighty Beat-And-RaiseInvestors Business Daily • 05/10/24
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/09/24
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast CancerBusiness Wire • 05/03/24
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg ShortageBusiness Wire • 05/01/24
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney TransplantationBusiness Wire • 04/11/24
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant RecipientsBusiness Wire • 04/08/24
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder CancerBusiness Wire • 04/05/24
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial CancerBusiness Wire • 04/01/24
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal CancerBusiness Wire • 03/18/24
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of DiseaseBusiness Wire • 03/14/24